Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2009 4
2010 2
2011 7
2012 4
2013 6
2014 4
2015 4
2016 9
2017 11
2018 4
2019 7
2020 8
2021 5
2022 5
2023 3
2024 3
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies.
Sicuranza A, Breccia M, Iuliano F, Gugliotta G, Castagnetti F, Lunghi M, Patriarca A, Intermesoli T, Luciano L, Russo Rossi A, Rege Cambrin G, Vucinic V, Malagola M, Malato A, Abruzzese E, D'Adda M, Galimberti S, Defina M, Sammartano V, Cafarelli C, Cencini E, Cartocci A, Pacelli P, Piciocchi A, Rughini A, Niederwieser D, Bocchia M. Sicuranza A, et al. Among authors: gugliotta g. Vaccines (Basel). 2025 Apr 16;13(4):419. doi: 10.3390/vaccines13040419. Vaccines (Basel). 2025. PMID: 40333294 Free PMC article.
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid Leukemia.
Mancini M, De Santis S, Monaldi C, Castagnetti F, Iezza M, Iurlo A, Cattaneo D, Galimberti S, Cerrano M, Capodanno I, Bonifacio M, Rossi M, Agostinelli C, Meggendorfer M, Haferlach T, Cavo M, Gugliotta G, Soverini S. Mancini M, et al. Among authors: gugliotta g. Clin Transl Med. 2025 Apr;15(4):e70163. doi: 10.1002/ctm2.70163. Clin Transl Med. 2025. PMID: 40275711 Free PMC article.
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice.
Pellegrini C, Casadei B, Broccoli A, Cantelli M, Gugliotta G, Gentilini M, Carella M, Stefoni V, Fabbri N, Gabrielli G, Argnani L, Mazzoni C, Maglio P, Bagnato G, Zinzani PL. Pellegrini C, et al. Among authors: gugliotta g. Ann Hematol. 2025 Mar;104(3):1757-1764. doi: 10.1007/s00277-025-06255-8. Epub 2025 Mar 1. Ann Hematol. 2025. PMID: 40025210 Free PMC article.
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study.
Casadei B, Argnani L, Broccoli A, Cantelli M, Gugliotta G, Gentilini M, Carella M, Stefoni V, Pellegrini C, Fabbri N, Gabrielli G, Mazzoni C, Maglio P, Bagnato G, Zinzani PL. Casadei B, et al. Among authors: gugliotta g. Blood Adv. 2025 May 13;9(9):2044-2047. doi: 10.1182/bloodadvances.2024015581. Blood Adv. 2025. PMID: 39993241 Free PMC article. No abstract available.
Efficacy and Safety of Frontline Single-Agent Rituximab in Extranodal Marginal Zone Lymphoma.
Mazzoni C, Argnani L, Casadei B, Broccoli A, Gabrielli G, Fabbri N, Gugliotta G, Pellegrini C, Carella M, Bagnato G, Gentilini M, Morigi A, Maglio P, Cantelli M, Stefoni V, Zinzani PL. Mazzoni C, et al. Among authors: gugliotta g. Eur J Haematol. 2025 Jan;114(1):70-78. doi: 10.1111/ejh.14306. Epub 2024 Sep 18. Eur J Haematol. 2025. PMID: 39295142 Free PMC article.
Psoriasis: a new adverse event of ibrutinib.
Rapparini L, Massi A, Baraldi C, Gugliotta G, Pileri A. Rapparini L, et al. Among authors: gugliotta g. Ital J Dermatol Venerol. 2024 Apr;159(2):205-207. doi: 10.23736/S2784-8671.23.07735-6. Epub 2024 Jan 29. Ital J Dermatol Venerol. 2024. PMID: 38287741 No abstract available.
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.
Luciano L, Latagliata R, Gugliotta G, Annunziata M, Tiribelli M, Martino B, Sica A, Esposito MR, Bocchia M, Galimberti S, Sorà F, Albano F, Palmieri R, Pregno P, Dragani M, Iovine M, Sica S, Iurlo A, Castagnetti F, Rosti G, Breccia M. Luciano L, et al. Among authors: gugliotta g. Ann Hematol. 2023 Jun;102(6):1375-1382. doi: 10.1007/s00277-023-05159-9. Epub 2023 Apr 20. Ann Hematol. 2023. PMID: 37079069 Free PMC article.
83 results